Xiu Laigui, the chairman, founded Xiu Laigui, 1995, is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing, chemical pharmacy and biopharmaceuticals, drug chain management and standard cultivation of Chinese herbal medicines.
The development pattern of Xiuzheng Pharmaceutical has two head offices, three national well-known trademarks of Xiuzheng, Tanya and Xingshu, and fourteen sales platforms. Since 2000, it has been ranked first in the comprehensive ranking of pharmaceutical enterprises in Jilin Province for 10 years, and ranked first in the profit of Chinese medicine enterprises in China since 2004, and its sales and profits are among the top ten in the pharmaceutical industry in China.
Extended data
Correcting over-standard events in pharmaceutical industry
event
On April 6, 2065, the State Food and Drug Administration of the United States issued an urgent notice to suspend the sale and use of 13 medicinal hollow capsule products because of suspected chromium exceeding the standard. These include antelope cold capsules produced by the pharmaceutical industry.
After the incident of "making medicinal capsules with industrial gelatin" was exposed, the revised pharmaceutical company official website was once hacked, and the webpage was changed to "Did you take my rotten shoes as capsules?" The first six lines.
Wang Zhiguang, senior vice president of Amendment Pharmaceutical, responded that the production date of the batch number submitted by CCTV was before the implementation of the new national standard, and the chromium content was not within the detection range.
event handling
Four days after CCTV exposed the "problem capsule", Zheng Xiu Pharmaceutical released the "Notice on the Handling Process of Antelope Cold Capsule Suspected of Excessive Chromium" through official website on April 19, 2065438, saying that it had recalled 199 suspected Antelope Cold Capsule and apologized to the public through its website.
According to the report, all production lines of antelope cold capsules have stopped production and conducted self-inspection. At the same time, the safety team has carried out internal quality inspection, procurement, circulation and other aspects of inspection and responsibility tracing, and actively cooperated with National Medical Products Administration to inspect capsule products.
Revision Pharmaceutical also said that it plans to invest 300 million yuan to build its own capsule production enterprise in the next two years. They deeply apologize for the inconvenience caused by this incident to consumers, customers, the government and the media. He also said that in future actions, the public will be informed of the follow-up progress in a timely manner.
Baidu Encyclopedia-Zheng Xiu Pharmaceutical Group